ASH 2022 | Clonotypic mass spectrometry with Easym assay for MRD detection in multiple myeloma
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, comments on the feasibility of clonotypic mass spectrometry with Easym assay for measurable residual disease (MRD) detection in the peripheral blood (PB) of patients with multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.
